User login
BETHESDA, MD. – Dr. John Hardy first theorized the amyloid cascade hypothesis in 1992. Since then, amyloid-beta has remained the prime focus of Alzheimer’s disease research and therapy. But as the understanding of Alzheimer’s pathogenesis deepens, critical genetic and environmental interactions with amyloid become ever more important in untangling the disorder’s mysteries.
In this interview at the National Institutes of Health’s Alzheimer’s Disease–Related Dementias 2016 Summit, Dr. Hardy of University College London Institute of Neurology discusses some of the issues behind treating and studying clinical differences in Alzheimer’s disease and other types of dementia.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @alz_gal
BETHESDA, MD. – Dr. John Hardy first theorized the amyloid cascade hypothesis in 1992. Since then, amyloid-beta has remained the prime focus of Alzheimer’s disease research and therapy. But as the understanding of Alzheimer’s pathogenesis deepens, critical genetic and environmental interactions with amyloid become ever more important in untangling the disorder’s mysteries.
In this interview at the National Institutes of Health’s Alzheimer’s Disease–Related Dementias 2016 Summit, Dr. Hardy of University College London Institute of Neurology discusses some of the issues behind treating and studying clinical differences in Alzheimer’s disease and other types of dementia.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @alz_gal
BETHESDA, MD. – Dr. John Hardy first theorized the amyloid cascade hypothesis in 1992. Since then, amyloid-beta has remained the prime focus of Alzheimer’s disease research and therapy. But as the understanding of Alzheimer’s pathogenesis deepens, critical genetic and environmental interactions with amyloid become ever more important in untangling the disorder’s mysteries.
In this interview at the National Institutes of Health’s Alzheimer’s Disease–Related Dementias 2016 Summit, Dr. Hardy of University College London Institute of Neurology discusses some of the issues behind treating and studying clinical differences in Alzheimer’s disease and other types of dementia.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @alz_gal
EXPERT ANALYSIS FROM THE ADRD SUMMIT 2016
